Company intelligence / Profile preview
Locus Biosciences
Morrisville, North Carolina, United Stateslocus-bio.com ↗
- Ownership
- Private
- Employees
- ~80
- Development stage
- Phase 2
01
Overview
Completed first human clinical trial in early 2021 with a crPhage product targeting E. coli in the urinary tract. Initiated Phase 2 trial of LBP-EC01 for UTIs in mid-2022.
- Therapeutic areas
- OncologyImmunologyNeurologyInfectious Diseases
- Modalities
- Engineered bacteriophage treatmentsCRISPR-Cas3 enhanced bacteriophage (crPhage)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Johnson & Johnson (Janssen Pharmaceuticals)BARDACARB-X
Beyond the preview
Go deeper on Locus Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Locus Biosciences.